Intrommune Therapeutics

Early Stage

Intrommune Therapeutics is a New York City-based biopharmaceutical company developing a new, simple treatment for food allergies.


Raised to Date: Raised: $157,806

Total Commitments ($USD)



Start Date


Close Date


Min. Goal


Max. Goal


Min. Investment


Security Type

Equity - Common

SEC Filing Type

RegCF / RegD 506(c)    Open SEC Filing

Price Per Share


Pre-Money Valuation


Rolling Commitments ($USD)

Reporting Date


Days Remaining
% of Min. Goal


% of Max. Goal


Likelihood of Max
Avg. Daily Raise


Create a free account today to gain access to KingsCrowd analytics.
Year Founded



Healthcare & Pharmaceuticals

Tech Sector



New York, New York

What if treating your allergies was as easy as….brushing your teeth? Well, with Intrommune Therapeutics, it now just might be! This New York City-based biopharmaceutical company is developing a toothpaste that uses oral mucosal immunotherapy (OMIT) to help people with peanut allergies overcome them. OMIT is based on allergy immunotherapy, which adheres to the idea that if patients receive tiny, carefully controlled amounts of the substance they are allergic to, their immune system learns that the substance is safe, and their allergic reactions become milder. Intrommune’s great-tasting, cavity-fighting toothpaste exposes patients to a low, safe dose of a peanut-derived protein in the toothpaste, with the goal of desensitizing the immune system’s reaction. They are developing this toothpaste in accordance to FDA guidelines, and there is no current FDA-approved treatment for any peanut for food allergy.
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Intrommune Therapeutics 07/07/2021 Self Managed - $0 Equity - Common Funded RegD 506(c)
Intrommune Therapeutics 06/29/2018 Netcapital $15,000,000 $157,806 Equity - Common Funded RegCF / RegD 506(c)
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$12.42 /month
billed annually
Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings (excluding risk)
Advanced company search ( with ratings)
Markets page filters and historical industry data
Get Edge Annual

Edge Pro

$41.58 /month
billed annually
Full site access including KingsCrowd's qualitative analyst reports.
Plan Includes:
Everything in Edge, plus
Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
Search and filter based on Analyst Reports
In-depth risk ratings for every raise
Get Edge Pro Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.

Create your first portfolio

Create your own startup investment portfolio on KingsCrowd.

Track all of your startup investments in one place using our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Intrommune Therapeutics on Netcapital
Platform: Netcapital
Security Type: Equity - Common
Valuation: $15,000,000

Follow company

Follow Intrommune Therapeutics on Netcapital

Buy Intrommune Therapeutics's Deal Report

Warning: according to the close date for this deal, Intrommune Therapeutics may no longer be accepting investments.

Intrommune Therapeutics Deal Report

Get KingsCrowd’s comprehensive report on Intrommune Therapeutics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Intrommune Therapeutics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Intrommune Therapeutics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge Pro